What a 2026 compounded tirzepatide price report does and doesn't tell you
A new price report pegs monthly compounded tirzepatide costs between $125 and $199 across seven online providers. Price is one data point, and it says nothing about whether treatment is right or safe for you.
Ozari Health published a 2026 price report on compounded tirzepatide. According to the headline and snippet, monthly costs range from $125 to $199 across seven online providers. That is the whole of what the reporting establishes.
What the report actually says
It is a price survey. It documents a spread of advertised monthly costs across a handful of sellers. That is useful context if you are trying to understand what the online market looks like right now.
What it does not say is anything about clinical quality, who is prescribing, how the medication is sourced, or whether any given provider runs a real medical intake. Price is one number. It is not a proxy for safety or legitimacy.
Compounded tirzepatide, briefly
Compounded tirzepatide is prescription medication prepared by a compounding pharmacy. It is not the same as an FDA-approved branded product, and compounded formulations are not FDA-approved. They are dispensed off-label where applicable, after a licensed physician reviews your case and writes the prescription.
What this means if you are considering care
Treat a price report as a starting point, not a shopping list. The questions that matter more than cost are who evaluates you, whether a real medical intake happens, and whether a physician actually approves the plan. A prescription is never guaranteed, and whether tirzepatide is appropriate depends on the individual.
At Live Vital, every protocol is physician-prescribed and requires a medical intake and physician approval. We are a nationwide telehealth practice, not a retail counter. We do not accept insurance, though HSA and FSA funds are generally eligible.
Outcomes vary from person to person, and nothing here is medical advice. If you want to understand your own options, you can read more about tirzepatide and semaglutide, or start a medical intake at /get-started.
Bottom line: the report is a snapshot of prices, nothing more. Decisions about GLP-1 medications belong with a licensed clinician who has reviewed your case.